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the general distinction between a targeted and a genome-
wide microarray needs to be scrutinised. Then we exam-
ine whether microarrays are ‘suitable tests’ to serve either 
a screening or a diagnostic purpose. Given the wide range 
of findings possibly generated by microarrays, the question 
arises whether microarrays actually promote or interfere 
with autonomous reproductive decision-making. Moreo-
ver, if variants of unknown clinical significance are identi-
fied, this adds to the burden and complexity of reproductive 
decision-making. We suggest a qualified use of microarrays 
in the prenatal context.
Introduction
Array-based molecular cytogenetic techniques (in short: 
microarrays) have for quite some time been routinely used 
in the postnatal setting, in particular to evaluate children 
Abstract Genomic microarray analysis is increasingly 
being applied as a prenatal diagnostic tool. Microarrays 
enable searching the genome at a higher resolution and 
with higher sensitivity than conventional karyotyping for 
identifying clinically significant chromosomal abnormali-
ties. As yet, no clear guidelines exist on whether microar-
rays should be applied prenatally for all indications or only 
in selected cases such as ultrasound abnormalities, whether 
a targeted or genome-wide array should be used, and what 
these should include exactly. In this paper, we present some 
ethical considerations on the prenatal use of microarrays. 
There is a strong consensus, at least in Western countries, 
that the aim of prenatal screening for foetal abnormalities 
should be understood as facilitating autonomous repro-
ductive choice for prospective parents. The tests offered 
should be valid and useful to reach that purpose. Against 
this background, we address several ethical issues raised by 
the prenatal application of microarrays. First, we argue that 
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with mental retardation or other abnormal phenotypes 
with unknown cause (Bejjani and Shaffer 2006; Shaffer 
et al. 2006; Stankiewicz and Beaudet 2007). Microarrays 
enable searching the entire genome for copy number vari-
ants (CNVs) at a higher resolution and with higher sensi-
tivity than conventional karyotyping, and can detect more 
clinically relevant abnormalities (Armengol et al. 2012; 
Savage et al. 2011; Wapner et al. 2012b; Zuffardi et al. 
2011). Because of this increased yield, microarrays are 
increasingly applied as a prenatal diagnostic tool. For the 
moment, microarray analysis will be performed on inva-
sively obtained foetal material, although considerable effort 
is being put in methods for genome-wide diagnostics by 
means of non-invasive prenatal testing (NIPT) (Kitzman 
et al. 2012; Srinivasan et al. 2013).
So far, no clear guidelines exist if and when to use 
microarrays prenatally. In 2010, the International Stand-
ards for Cytogenomic Arrays (ISCA) Consortium pub-
lished a consensus statement in which the evidence at that 
time was thought to be insufficient to allow recommenda-
tions regarding prenatal applications (Miller et al. 2010). 
The ISCA proposed to use traditional cytogenetic methods 
instead. Earlier, in 2009, the American College of Obstet-
rics and Gynecology (ACOG) recommended to use con-
ventional karyotyping as the principal cytogenetic tool in 
prenatal diagnosis, although a targeted array that focuses 
on detecting chromosomal abnormalities for known genetic 
syndromes was proposed as an adjunct tool in case of a 
combination of abnormal ultrasound findings and a nor-
mal conventional karyotype (ACOG 2009; Miller et al. 
2010). The Italian Society of Human Genetics (SIGU) has, 
in 2012, recommended a genome-wide array instead of a 
targeted array in this situation (Novelli et al. 2012). Some 
expect or recommend microarray analysis to become the 
‘first-tier test’ for all pregnancies because of its increased 
yield, irrespective of the indication (Bernhardt et al. 2013; 
Fiorentino et al. 2013; Maya et al. 2010; Savage et al. 
2011). Others are more reticent about introducing this test 
prenatally. This reticence is mainly due to the fact that 
microarrays identify CNVs that can be categorised as being 
likely benign, likely pathogenic or a variant of unknown 
clinical significance (VOUS) (Hillman et al. 2011), and that 
arrays generate more VOUS than karyotyping (Armengol 
et al. 2012; Cavalli et al. 2012; Dondorp et al. 2012). Thus, 
finding more clinically relevant abnormalities comes at the 
price of finding more VOUS: estimations of the percent-
age of VOUS in all prenatal samples vary from 0.3–1 %, 
depending on the population tested and the platform used 
(Armengol et al. 2012; Coppinger et al. 2009; Wapner et al. 
2012a).
Despite the differing opinions about the prenatal applica-
tion of microarrays, they are already used for several indi-
cations, and mostly applied in case of foetal abnormalities 
shown by foetal ultrasound scans (Hillman et al. 2012; 
Leung et al. 2011; Savage et al. 2011; Van den Veyver et al. 
2009). Most pregnancies with ultrasound anomalies show a 
normal karyotype and remain without an aetiological diag-
nosis if only conventional karyotyping is applied. Testing 
by microarrays at a higher resolution and for more abnor-
malities is therefore supposed to be beneficial because of 
increased detection rates (Faas et al. 2010; Hillman et al. 
2012; Leung et al. 2011; Savage et al. 2011; Van den Veyver 
et al. 2009; Zuffardi et al. 2011): it can provide around 6 % 
extra diagnoses in this situation (Armengol et al. 2012; 
Hillman et al. 2012; Wapner et al. 2012b). Another indica-
tion to perform microarray testing is to interpret chromo-
some rearrangements detected by conventional karyotyping 
of which the clinical consequences are unsure. Microar-
rays allow for determining the size of the imbalance and 
the gene content, which may help to distinguish between 
pathogenic versus benign findings and to shed some light 
on the associated phenotype (Armengol et al. 2012; Hill-
man et al. 2012; Wapner et al. 2012b). Moreover, microar-
ray testing can be offered to women with an increased risk 
for trisomies 21, 18 and 13, either based on risk-assessment 
outcomes or advanced maternal age. This will improve the 
overall detection rate of clinically significant chromosomal 
abnormalities compared to conventional karyotyping, since 
microarray may reveal around 1.7 % more cases in this 
group (Maya et al. 2010; Park et al. 2010; Wapner et al. 
2012b). For this same reason, it has also been proposed to 
offer microarray as a first-tier test to all pregnant women 
(Armengol et al. 2012; Fiorentino et al. 2013; Maya et al. 
2010; Van den Veyver et al. 2009).
To address the question what kind of microarray testing 
should be offered and to whom, it is morally important to 
assess whether this would be done for the purpose of find-
ing a diagnosis or for screening and whether a targeted 
or a genome-wide microarray is a ‘suitable test’ for these 
purposes. In this paper, we will first briefly elucidate the 
notion of a suitable test and show how this relates to the 
normative framework for medical testing (diagnosis and 
screening). We will then go on to scrutinise the distinction 
between a targeted and a genome-wide microarray, and 
show that these notions are in need of a conceptual clarifi-
cation to allow insight into the ethical implications of both. 
Next, we assess whether microarrays serve a diagnostic or 
a screening purpose, and whether they can be seen and jus-
tified as ‘suitable’ tests.
A suitable test
One of the well-known Wilson and Jungner criteria for pop-
ulation screening is that there must be a suitable test (Wil-
son and Jungner 1968). This notion refers to the quality of 
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a test in relation to its aim. The quality of a genetic test can 
be determined on different levels: analytical validity, clini-
cal validity and clinical utility. Analytical validity is the 
ability of the test to accurately determine the genotype of 
interest. Clinical validity is the accuracy with which the 
test can predict a phenotype. This comprises both formal 
test characteristics as well as predictive value in a specific 
population. A diagnostic test is a test with ~100 % positive 
and negative predictive value. A screening test may have a 
somewhat lower score in this respect and still be suitable, if 
a positive result can be followed up by a test of diagnostic 
quality. Finally, clinical utility refers to quality in the wider 
sense of the ability of a genetic test to generate information 
that is relevant and important given the specific aim of the 
testing procedure (Javaher and Schmidtke 2010). Taken in 
this wider sense, a ‘suitable test’ is one that would show a 
positive balance of aim-related advantages and unavoidable 
disadvantages (drawbacks and costs) of testing.
At this level, the notion of a suitable test connects with 
ethical acceptability, more specifically with the conditions 
of ‘appropriateness’ and ‘proportionality’ (Beauchamp 
and Childress 2009). To be appropriate, a medical activ-
ity must lead (or contribute) to achieving a legitimate aim 
of medicine. With regard to genetic testing, a distinction 
must at this point be made between the aims of diagno-
sis and screening. In clinical care, the aim of testing is to 
clarify the medical problem with which the patient pre-
sents, to allow treatment or secondary prevention. Prena-
tal diagnosis (indicated either in view of a genetic risk that 
was known prior to conception or as diagnostic follow-up 
testing in a prenatal screening context) is a special case, 
as the aim of testing in this context is to clarify the situa-
tion to either reassure the prospective parents, or to allow 
them to make a decision about whether or not to continue 
the pregnancy to term. The aim of screening programmes 
generally is the early detection of disease or risk factors in 
persons without clinical symptoms or complaints, so as to 
allow timely intervention (treatment or primary prevention) 
expected to lead to a significant health gain on a population 
level. Prenatal screening, however, is a special case here. 
There is a strong consensus, at least in Western countries, 
that the aim of prenatal screening for foetal abnormalities 
should be understood as facilitating autonomous reproduc-
tive choice for pregnant women (and their partners), rather 
than to achieve a population health gain by trying to pre-
vent the birth of children with congenital abnormalities 
(Health Council of the Netherlands 2008; UK NSC 2007).
Assuming that medical testing is appropriate in view of 
a legitimate aim, the further condition of ‘proportionality’ 
requires that any drawbacks, burdens and costs are propor-
tional to the importance of achieving that end. For instance, 
a costly and burdensome test which is known beforehand 
only to have a limited impact on clinical management, 
may well be disproportional. Moreover, if there is a choice 
between different ways to reach the same end, the least 
risky, burdensome, costly, etc. alternative should in prin-
ciple be chosen (this is often referred to as the condition 
of ‘subsidiarity’) (American College of Medical Quality 
2011).
In addition to requiring a legitimate aim and a suit-
able test (in the sense just given), the ethical acceptability 
of medical testing requires that the person to be tested (or 
this person’s representative) has given his or her informed 
consent. This presumes a professional duty to provide him 
or her with the information needed for making a well-con-
sidered decision, including information about the aim and 
nature of the procedure, but also about implications of pos-
sible outcomes for the testee and any other stakeholders.
As we will show, the implementation of microarray test-
ing in the prenatal testing cascade challenges some of these 
conditions of what, from the perspective of ethical accept-
ability, would be a suitable test.
Genome‑wide versus targeted microarray: a moot 
distinction
Generally, a distinction is made between a genome-wide 
and a targeted microarray, but the meaning of the adjectives 
‘genome-wide’ and ‘targeted’ is not as clear as it may seem 
at first sight.
First, both kinds of tests are genome-wide in the sense 
that both search throughout the entire genome for possi-
ble submicroscopic deletions and duplications. A targeted 
microarray, however, is designed to only cover genomic 
regions across the genome that are known to be associated 
with phenotypic abnormalities: thus, it can focus on vari-
ous regions throughout the whole genome and include as 
many or as few microdeletion and duplication syndromes 
as thought to be needed (Savage et al. 2011). Moreover, the 
density of probes in both targeted and genome-wide arrays 
can vary. Whereas karyotyping can only detect anomalies 
to a resolution of 5–10 Mb, bacterial artificial chromo-
somes (BAC) arrays and high-resolution oligonucleotide 
arrays are capable of detecting changes at a much higher 
resolution—up to 50–100 Kb (Edelmann and Hirschhorn 
2009; Scott et al. 2013). Microarrays can also be designed 
to have a different resolution for specific parts across the 
genome. For example, ‘critical regions’ that are known 
for being associated with specific abnormalities, may be 
searched at a higher resolution (thus detecting smaller dele-
tions and duplications), whereas the remaining regions 
(so-called backbone regions) are searched for deletions 
and duplications of a greater size only (Edelmann and 
Hirschhorn 2009; Savage et al. 2011; Zuffardi et al. 2011). 
Since every microarray is biased in the sense that its design 
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is based on a decision of what size and kind of deletions 
and duplications are to be detected, a so-called “unbiased 
whole-genome array-CGH” (Veltman and de Vries 2006) 
does not exist. It is therefore important to know what par-
ticular design an array has (resolution for critical and back-
bone region).
Second, the main feature of targeted prenatal microar-
rays, that they only cover genomic regions known to be 
associated with phenotypic abnormalities, has the advan-
tage (and purpose) to minimise the number of VOUS, to 
equally minimise the emotional burden and counselling 
difficulties associated with VOUS (ACOG 2009; Kleeman 
et al. 2009; Le Caignec et al. 2005; Reiff et al. 2012; Shaf-
fer et al. 2008). Still, their design means that the ‘target’ is 
not per se related to the initial indication. The microarray is 
mostly used for a diagnostic purpose, namely to explain a 
specific unclear (mostly foetal ultrasound scan) abnormal-
ity, but a targeted array targets all known genomic regions, 
whatever the indication. In that regard, it clearly differs 
from targeted testing by molecular methods for rapid ane-
uploidy detection (RAD) (Faas et al. 2011): whereas the 
scope of RAD is explicitly limited to the few abnormalities 
for which the pregnant woman is found to be at increased 
risk, the scope of a targeted microarray is not limited to a 
few indication-related specific genomic regions only. We 
therefore conclude that ‘targeted’ in the prenatal context 
is not a clear concept, but has two different meanings. On 
the one hand, targeted indicates that the scope of the tech-
nique is explicitly limited to the diagnostic question, i.e. 
to the purpose of identifying one or only a limited number 
of well-described disorders indicated by a specific symp-
tom or risk assessment. This meaning applies to the nar-
row RAD test. On the other hand, targeted indicates that 
the scope of a test is limited in that it does reveal all known 
clinically relevant abnormalities and does not—or at least 
as little as possible—generate unclear findings. In the case 
of prenatal microarrays, this second meaning of targeted de 
facto applies: although there is a specific reason to perform 
an array—a diagnostic indication—the design of the array 
itself is not specifically tailored to this indication. This is 
not only a terminological issue, but bears ethical relevance 
too. From a normative perspective, the scope of a diagnos-
tic test should be adjusted as much as possible to the initial 
diagnostic question. This basic conceptual clarification is 
an essential part of the justification for doing that specific 
test (criteria of appropriateness, proportionality and sub-
sidiarity). In the case of prenatal microarrays, this does not 
evidently hold.
As our analysis shows, the terms ‘genome-wide’ and 
‘targeted’ are equivocal and in our view therefore not suit-
able for indicating the ethically relevant characteristics 
of the two kinds of microarrays. To avoid any confusion 
about what ‘genome-wide’ and ‘targeted’ in the prenatal 
context mean when indicating diagnostic tests, we propose 
to use the terms ‘undirected’ and ‘directed’ for describing 
the arrays instead. ‘Undirected’ arrays search the whole 
genome, or part(s) of it, for all CNVs, both those that are 
associated with a known phenotype and those of uncertain 
clinical significance. ‘Directed’ microarrays aim to provide 
maximum detection of all clinically significant CNVs. The 
term ‘targeted’ will be reserved for tests whose scope is 
attuned to the diagnostic question (see Table 1).
From this classification, it follows that an undirected 
microarray can never be targeted. A directed array can 
sometimes be understood as targeted, namely, if and inso-
far the diagnostic question is totally undefined, as may be 
the case when unclear foetal ultrasound markers are found. 
If the direction of the diagnostic search cannot be derived 
from the markers, it may be necessary to look for all known 
and clear aberrations (directed microarray) to enlarge the 
chance of finding a clarification. However, a specific ultra-
sound finding, for example a foetal heart defect, indicates 
that the diagnostic search by microarray can focus on 
regions associated with cardiogenetic diseases only.
The use of microarrays: between prenatal diagnosis, 
screening and research
The case for targeted arrays
Microarrays are increasingly used as a follow-up test in 
a prenatal diagnosis context. One application is to clarify 
chromosome rearrangements detected by conventional 
karyotyping. In that case, the focus and aim are rather 
straightforward: to give more clarity about the nature and 
the phenotypical consequences of a specific chromosomal 
abnormality. Such information is important for pregnant 
women to make a well-informed decision about whether 
to terminate or continue the pregnancy. In this situation, 
a targeted microarray focusing on the specific region that 
needs clarifying only should ideally be applied to answer 
the diagnostic question. An array that focuses on more 
regions would exceed the scope of the question and would 
in that sense not be appropriate, but amount to excessive 
testing.
Table 1  Ideal types of prenatal microarray testing
Denotation Characteristic of test
Undirected The test seeks all, both clear and unclear, aberrations 
(known and unknown CNVs)
Directed The test seeks all known and clear aberrations (known 
CNVs)
Targeted The test only seeks the aberrations indicated by the diag-
nostic question
167Hum Genet (2014) 133:163–172 
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The most frequent application of microarrays in prenatal 
diagnosis is to clarify foetal ultrasound abnormalities, and 
in this situation the focus is less clear-cut. First and second 
trimester ultrasound scans may show major structural anom-
alies as well as markers that may indicate heterogeneous 
abnormalities and syndromes. In the latter case, as will be 
discussed below, a targeted array will often not be possible. 
However, the cause of (some) major and isolated structural 
abnormalities may be relatively easy to identify (de Wit 
et al. 2013). Whenever this is the case, it would seem that an 
array meant to clarify the findings need not look beyond the 
particular genomic region(s) associated with them.
But even in cases where it would be possible to target 
the design of the array itself or to target the analysis of the 
data obtained by an (un)directed microarray (Bejjani and 
Shaffer 2006; Vermeesch et al. 2007), to the best of our 
knowledge not a targeted but a directed or an undirected 
array is generally used. Directed arrays as described in the 
literature and as used at various institutions cover around 
75–200 genomic disorders (Zuffardi et al. 2011) and most 
of these “known deletion and duplication syndromes would 
not present with any specific prenatal risk factors or char-
acteristic ultrasound findings” (Fruhman and van den 
Veyver 2010). This suggests that in practice, the indication 
or diagnostic question does not determine the decision of 
what test platform to use or what analysis to perform. The 
same arrays are used for pre- and postnatal samples and for 
different indications, mainly for practical and/or financial 
reasons. Since directed (and targeted) arrays necessitate 
frequent updating to include new relevant CNVs, some 
commentators insist that such arrays are simply not cost-
effective and impractical from a laboratory point of view 
(Faas et al. 2010; Vetro et al. 2012). A similar argument 
is made by Rehm (2013) with regard to next-generation 
sequencing (NGS). She remarks that “(a)lthough disease-
targeted testing is likely to remain useful for the short term, 
laboratories are faced with the never-ending incremental 
costs to develop and to validate each new disease-targeted 
panel, as well as to update constantly the content of exist-
ing panels as new genes are identified. This burden is caus-
ing laboratories to consider more efficient approaches than 
targeted testing.”
However, these considerations cannot conceal that in 
situations where a targeted test would suffice to clarify the 
karyotyping or ultrasound findings, the use of wider tests 
marks a step from prenatal diagnosis to a wider prenatal 
screening paradigm, where (un)directed microarrays serve 
as a tool to identify any foetal abnormality detectable by 
microarray, rather than just answer the clinical question. 
The same shift is behind offering (un)directed microar-
rays to pregnant women at increased risk for common ane-
uploidies (trisomies 21, 18 and 13) (Armengol et al. 2012; 
Fiorentino et al. 2013).
Excessive testing is ethically problematic, as it adds 
to the unavoidable drawbacks of testing without a pos-
sible justification in terms of aim-related advantages for 
the testee(s). From a proportionality perspective, a test 
with such implications can hardly be suitable for prenatal 
diagnosis. This problem may seem to disappear with the 
implicit shift from prenatal diagnosis to prenatal screen-
ing, where the aim of testing for foetal abnormalities is 
no longer bound by an indication. If prenatal screening is 
aimed at providing women or couples with whatever infor-
mation about the foetus they may find relevant in view of 
autonomous reproductive decision-making, there may seem 
to be no such thing as ‘excessive testing’. Some have fol-
lowed this path towards proposing that all pregnant women 
should be offered an (un)directed microarray (Fioren-
tino et al. 2013). However, even if it could be argued that 
a ‘maximum yield approach’ would be appropriate given 
the aim of prenatal screening, more is needed to speak of 
a suitable test, especially in view of what this would entail 
for the testees in terms of the balance of benefits and draw-
backs (‘proportionality’).
The place for directed arrays
If multiple ultrasound abnormalities are found, this indi-
cates that the pregnancy could be ‘at-risk’, but the ques-
tion at risk for what can mostly not be answered exactly. 
An enlarged nuchal translucency (NT) thickening (at 11–
12 weeks of gestation), usually defined as ≥3.0–3.5 mm, is 
associated with an increased risk of congenital cardiac dis-
orders and a number of genetic and non-genetic disorders, 
thus giving reason for follow-up testing (Sonek 2007). The 
mid-trimester ultrasound scan examines overall basic foe-
tal anatomy including, amongst other things, head, heart, 
abdomen, spine, limbs and extremities (Salomon et al. 
2011) and is used to identify a broad range of aberrations 
indicating heterogeneous abnormalities and syndromes. 
The broad and unselective character of these ultrasound 
scans brings about that if foetal anomalies are found, it will 
not always be possible to specify the diagnostic question 
and, thus, also to limit the scope of the follow-up diagnos-
tic test to specific parts of the genome.
If the aim of a directed array is to clarify unspecific ultra-
sound findings by identifying their possible cause, such 
an array would in so far be ‘targeted’: a directed micro-
array may identify 6 % more clinically significant CNVs 
than conventional karyotyping would do. Indeed, it can be 
argued that offering an ultrasound screen involves a duty to 
as much as possible clarify any unclear findings to either 
provide reassurance to pregnant women or to allow them to 
make a meaningful decision about whether or not to con-
tinue the pregnancy. But even if answering to an obvious 
indication for follow-up testing, the use of a directed array 
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in such cases blurs the distinction between diagnosis and 
screening: while giving a better chance of clarifying the 
earlier findings for the prospective parents, at the same time 
the test will detect any other submicroscopic chromosomal 
abnormalities known to be relevant for the health prospects 
of the future child.
In the literature, an undirected array has regularly been 
referred to as a “diagnostic screen” (Veltman and de Vries, 
2006) or as “genome wide screening” (Faas et al. 2010; 
Srebniak et al. 2012). However, as our analysis suggests, 
this qualification also applies to the use of directed arrays, 
even where this approach would be appropriate (rather 
than excessive) follow-up testing. De facto, the use of such 
arrays comes down to scanning the foetal genome for any 
possible abnormality, related or unrelated to the ultrasound 
findings. As a result, prenatal microarrays have an ambigu-
ous character, which tends to obscure their purpose as a 
follow-up test. This may explain why publications about 
prenatal microarrays do not usually specify the percent-
age of results that actually answers the diagnostic question 
raised by ultrasound abnormalities. Neither is the classical 
distinction made between intended and incidental findings 
when indicating the yield of microarrays; this distinction 
seems to be fading with the shift towards screening for any 
(known) genetic abnormality. With this implicit shift, it 
also becomes less obvious why one would use a directed 
instead of an undirected array in case of unspecific ultra-
sound abnormalities.
The problem with undirected arrays
Proponents of an undirected array want to optimise the 
identification of all possibly clinically relevant CNVs. 
To detect these, both known and unknown regions are 
included in the testing array. A directed approach is seen 
as disadvantageous in that it will miss yet unknown clini-
cally important aberrations (Choy et al. 2010; Faas et al. 
2010; Tyreman et al. 2009). But it is far from evident 
that the extra yield of an undirected array gives a better 
chance of clarifying unspecific ultrasound findings. In 
most cases, what it adds is not a more adequate diagnosis, 
but VOUS and the hope that through further classifica-
tion and research, VOUS may be turned into meaningful 
findings (Shaffer et al. 2012; Wapner et al. 2012b). This 
entails assessing “clinical findings, literature, available 
databases, and gene content and size to determine whether 
there (is) sufficient information on which to base the pre-
diction of phenotype and, if so, whether the phenotype (is) 
of sufficient clinical relevance to be reported” (Wapner 
et al. 2012b). In other words: if a VOUS is classified, this 
will to a large extent be based on estimation and subjec-
tive evaluation of its possible meaning (Alesi et al. 2013). 
This may explain why, next to the differences in the array 
design, estimations on the number of VOUS vary from 
around 0.4 to 12 % (D’Amours et al. 2012; Shaffer et al. 
2012). The conclusion must be that for lack of clinical 
validity, undirected microarrays are a research tool rather 
than an instrument of clinical care. This is also appar-
ent from regular remarks in the literature saying that the 
number of VOUS will decrease as ‘genome-wide’ arrays 
will be applied more often, and more novel clinically rel-
evant CNVs will be detected (Hillman et al. 2012; Park 
et al. 2011). Or, as De Wit et al. (2013) state: “To allow 
the discovery of new pathogenic CNVs, whole genome 
array platforms should be recommended in the prena-
tal setting (…).” From an ethical point of view, there is 
a clear danger here that ignoring the distinction between 
research and care will lead to turning pregnant women 
into research subjects without their knowledge and con-
sent. As Bassem et al. (2006) have remarked, “(…)whole 
genome arrays are explorative by design and by purpose.” 
They therefore want to reserve undirected arrays for 
research purposes only, and propose to use directed arrays 
in diagnostic laboratories to protect patients against possi-
ble wrong interpretations. “After all”, they say, “we serve 
patients, not study subjects.”
Why indeed burden pregnant women with VOUS if 
this will not lead to a better diagnosis? The implicit ‘shift 
towards screening’ provides proponents of undirected 
arrays with a simple argument: because any information 
that something may be wrong with the foetus can be rel-
evant for the decision to continue or abort the pregnancy. 
For instance, according to McGillivray et al. (2012) it 
would be paternalistic of professionals to withhold infor-
mation about VOUS, because “(a) result of uncertain 
significance is still information” and “(i)f it is all about 
choice, then, no option or information potentially relevant 
to a woman’s choice and her decision-making processes 
should be withheld.” They add that professionals should 
not be held responsible for women’s decisions to terminate 
a pregnancy in case of unclear findings. But from an ethical 
point of view, this equation of a ‘maximum yield approach’ 
to microarray testing with ‘facilitating autonomous repro-
ductive choice’ as the accepted aim of prenatal screening is 
very simple. It ignores the crucial question how generating 
(further) unclarities would possibly serve this purpose. The 
message “we have found something in your foetus, but we 
do not know what it means” cannot reasonably be seen as 
relevant and helpful for prospective parents’ reproductive 
decision-making. Choices must be meaningful to be worth-
while. If they are not, the problem is not just that repro-
ductive autonomy becomes an empty concept, but also that 
its pursuit comes at a price that is no longer proportional, 
given the added burdens of anxiety and stress and the pos-
sible long-term impact of a decision to terminate a wanted 
pregnancy for what may have been false alarm. In terms 
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of the ethical framework set out earlier in this paper, the 
conclusion must be that undirected arrays are not a suitable 
test, neither for the purpose of prenatal diagnosis, nor for 
that of prenatal screening.
Of course, the issue of unclear test results is not new 
and unclear findings are difficult to completely avoid in 
prenatal testing. Conventional karyotyping may also gener-
ate results of which the clinical significance is unclear and 
even a directed microarray may incidentally reveal unclear 
findings. The same holds for the use of prenatal ultrasound. 
Analysts and clinicians are used to deal with these situa-
tions, and especially clinicians may be expected to act pru-
dently and take into account the principle of non-malef-
icence when reporting test results to their patients. Still, 
these latter situations have to be distinguished from the sce-
nario that unclear findings are deliberately generated—as is 
the case with undirected microarrays.
In our view, professionals who want to offer undi-
rected arrays to their patients should make clear that the 
main purpose of doing so is research: to contribute to the 
steadily growing knowledge about genotype–phenotype 
relations, and thereby to reduce the amount of VOUS. 
But it may well be that in some cases individual patients 
would directly benefit from participating in this research, 
as some unclear findings may be clarified swiftly and 
sufficiently enough to provide them with relevant infor-
mation (even though still ahead of formal proof of valid-
ity). This possibility may be a reason why well-informed 
patients may find it worthwhile to consent to participat-
ing in such research, while accepting that this comes at a 
price of being confronted with more unclear or ambiguous 
outcomes than would otherwise be the case. Still we think 
that, as part of the pre-test and consent procedure, pro-
fessionals offering such ‘experimental diagnosis’ should 
make clear to the woman or the couple that ‘true VOUS’ 
will not be reported to them.
Informed choice and counselling for microarray testing
Ganesamoorthy et al. (2013) have recently suggested that 
“the issue of balancing the use of the highest resolution 
arrays to maximise detection against the drawbacks of 
novel or uncertain findings may best be managed by giv-
ing parents the option of high-resolution or low-resolution, 
targeted, prenatal analysis.” We do not agree. If undirected 
arrays are unsuitable precisely because they undermine 
rather than serve autonomous decision-making by pregnant 
women and their partners, offering this choice in the name 
of that ideal is a non-starter. It seems a thin disguise for the 
attempt to preserve the option of using genome-wide arrays 
while relegating the responsibility to the patient. However, 
leaving the decision to the woman or the couple may well 
be an option where there would be a choice between a tar-
geted and a directed array. In cases where a targeted array 
would be an appropriate follow-up test for karyotyping 
or ultrasound findings, opting for a directed array would 
reflect the shift from diagnosis to screening. If only the 
prospective parents are aware of this, there seems nothing 
wrong with allowing them to choose this option, assuming 
that a directed array can more easily be justified as a suita-
ble test for prenatal screening purposes, than an undirected 
one. Allowing this choice between a targeted follow-up test 
and a wider screening test is similar to the ‘individualised 
choice’ between a targeted RAD test and karyotyping (de 
Jong et al. 2011b).
This still raises the question how to provide prospec-
tive parents with adequate information to facilitate them 
to make an informed choice whether to be tested or not, 
and what outcomes to receive or not. The traditional inter-
pretation of meaningful informed consent is that testees 
are in the pre-test situation informed about all conditions 
tested for, so that they can indicate what results they want 
to receive or not. It is clear that in case of a microarray 
test, this traditional interpretation of informed consent is 
untenable. It is impossible to extensively inform prospec-
tive parents about all the possible findings, including their 
clinical consequences. To do so would probably result in 
such an overload of information, that parents will in fact 
be incapacitated to give their informed consent. Catego-
rising findings may be the best and in fact the only fea-
sible option in the case of microarrays (de Jong et al. 
2011a).
To ensure that prospective parents’ views and prefer-
ences are taken into account, pre- and post-test counsel-
ling has to satisfy more than the requirements of adequate 
information and non-directiveness alone. The ‘interpretive 
model’ of the professional–patient relationship as intro-
duced by Emanuel and Emanuel (1992) seems to com-
ply best with what is needed in this situation. This model 
allows for a collaboration of the professional and the preg-
nant woman to choose the test option that suits the wom-
an’s situation and preferences best. To reach that aim, the 
professional informs her about the available options and 
helps the woman to clarify her own wants and values, to 
reach the decision that best fits her.
Conclusion
Microarrays enable identifying more clinically signifi-
cant abnormalities than conventional karyotyping and this 
is usually seen as a benefit, also in the prenatal context. 
Although we acknowledge the advantages of microar-
rays, we have also shown the drawbacks of the fact that the 
phenotypical consequences of many CNVs are uncertain. 
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We noted a tendency to use broader arrays than would be 
needed for clarifying karyotyping or ultrasound outcomes 
and an implicit shift from a prenatal diagnosis to a prena-
tal screening paradigm. This causes microarrays to have an 
ambiguous character. A clear distinction should be made 
between targeted, directed and undirected microarrays. If 
the indication pregnant women present with is clear, diag-
nostic testing should be done by what we have defined as 
a targeted microarray, ideally focussing on regions that 
are associated with the specific type or category of earlier 
findings. If, for instance, former outcomes point to cardiac 
problems, a targeted array would not look for CNVs asso-
ciated with neurogenetic abnormalities. If such an array 
is not available, or cannot be made available at a reason-
able cost, or if there are other justified reasons to apply a 
broader microarray, a directed microarray may be a suit-
able test. With regard to undirected arrays, we have sug-
gested that generating VOUS serves a research purpose and 
does not contribute to the aim of autonomous reproductive 
decision-making.
More in general, the current prenatal application of 
microarrays seems to be complicated by the fact that the 
development of this technique and the gain of knowl-
edge about its outcomes are still in progress: the applica-
tion is therefore taking place in the intermediate phase 
between research and implementation. As a result, deci-
sions have still to be made about what possible find-
ings to include in a testing array or not. In that regard, 
the prenatal use of microarrays may reflect a so-called 
‘extemporaneous’(Wilfond and Nolan 1993) translation 
of research into clinical care, instead of a well-balanced 
introduction of this technique after a profound evaluation 
of clinical, empirical and normative issues. With increasing 
knowledge, it may be possible to differentiate microarrays 
per diagnostic question to offer a suitable test and a clear 
answer to the medical question at hand.
For now, prospective parents will be confronted with 
the question whether they want to terminate or continue 
the pregnancy affected with any of the CNVs found. Since 
selective abortion is an emotionally and ethically charged 
decision, providers of prenatal tests have the obligation to 
carefully decide what findings they will confront prospec-
tive parents with and where the line between beneficial and 
maleficent provision of information will be passed. Allow-
ing pregnant women an ‘individualised choice’ between a 
targeted follow-up test and a wider screening test (directed 
microarray), may be an alternative. This option is in line 
with the aim of prenatal screening and offers women or 
couples the opportunity to choose the test that best fits their 
individual wants and needs.
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